Literature DB >> 3291041

Terodiline in the treatment of diurnal enuresis in children.

M Elmér1, J P Nørgaard, J C Djurhuus, T Adolfsson.   

Abstract

Efficacy and tolerance of the anticholinergic and calcium antagonistic drug terodiline (Mictrol) were investigated in comparison to placebo in 42 children with diurnal enuresis. The study was double-blind with a modified cross-over design with 2 treatment periods of 4 weeks. Terodiline in a daily dose of 25 mg was well tolerated. A statistically significant decrease in the number of wet episodes per day was found with terodiline when compared to placebo. In addition a high patient preference for terodiline was observed. This study shows that terodiline is effective in the treatment of daytime enuresis in children. The low incidence of side-effects also favours the use of terodiline in children.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291041     DOI: 10.3109/02813438809009301

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  4 in total

Review 1.  Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics).

Authors:  Aniruddh V Deshpande; Patrina H Y Caldwell; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Canadian Urological Association guideline for the treatment of bladder dysfunction in children.

Authors:  Kourosh Afshar; Joana Dos Santos; Anne-Sophie Blais; Darcie Kiddoo; Nafisa Dharamsi; Mannan Wang; Maryam Noparast
Journal:  Can Urol Assoc J       Date:  2021-02       Impact factor: 1.862

Review 3.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

4.  Terodiline in the treatment of nocturnal enuresis in children.

Authors:  M Ishigooka; T Hashimoto; I Sasagawa; K Izumiya; T Nakada
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.